Novo Nordisk CEO: Oral Semaglutide Launch In 2020, Novel Obesity Drugs Sought
Executive Summary
Novo Nordisk's GLP-1 franchise is advancing strongly and will be reinforced later this year by the expected approval of the ground-breaking oral semaglutide diabetes therapy, said CEO Lars Fruergaard Jørgensen
You may also be interested in...
Lilly's Trulicity Shows Unique Cardiovascular Outcomes Benefit, Albeit A Modest One
At the ADA annual meeting, Lilly reported positive results from REWIND, a cardiovascular outcomes trial studying the GLP-1 agonist Trulicity in a broad population of patients with and without established CV disease.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.